[en] Hypertension is a major cardiovascular risk factor in diabetic subjects. Recent trials have suggested that blood pressure objectives should be < or = 140/80 mmHg. However, there is currently no evidence supporting any particular preferential drug strategy for this treatment objective.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Marre, M.
Bouhanick, B.
Hadjadj, S.
Weekers, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
Language :
French
Title :
Contribution de l'hypertension arterielle au risque vasculaire du diabetique.
Alternative titles :
[en] Contribution of arterial hypertension to vascular risk in diabetic patients
Stamler, J., Vaccaro, O., Neaton, J.D., Wentworth, D., For the Multiple Risk Factor Intervention Trial research group : Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screemed in the multiple risk factor intervention trial (1993) Diabetes Care, 16, pp. 434-444
Norgaard, K., Feldt-Rasmussen, B., Borch-Johnsen, K., Saelan, H., Decken, T., Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus (1990) Diabetologia, 33, pp. 407-410
Marre, M., Microalbuminuria and prevention of renal insufficiency and cardiovascular diseases American (1998) Journal of Hypertension, 11, pp. 884-886
Marre, M., Fabbri, P., Berrut, G., Bouhanick, B., The concept of incipient diabetic nephropathy and effect of early antihypertensive intervention. Chapter 35 (1997) The Kidney and Hypertension in Diabetes Mellitus, pp. 351-360. , third Mogensen CE (ed.), Kluwer Academic Publishers, Boston, Dordrecht London
Chatellier, G., Zapletal, E., Lemaitre, D., Menard, J., Degoulet, P., The number needed to treat : A clinically useful nomogrem in its proper context (1996) BMJ, 312, pp. 426-429
Report of the expert committee on the diagnosis and classification of diabetes mellitus (1997) Diabetes Care, 20, pp. 1183-1197
Bauduceau, B., Chatellier, G., Cordonnier, D., Marre, M., Mimran, A., Sauvanet, J.P., Valensi, P., Balarac, N., Hypertension artérielle et diabète (1996) Diabète et Métabolisme, 22, pp. 64-76
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38 (1998) BMJ, 317, pp. 703-713
Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlöf, B., Elmfeldt, D., Julius, S., Menard, J., Westerling, S., For the HOT Study Group effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : Principal results of the Hypertension Optimal Treatment (HOT) randomised trial (1998) Lancet, 351, pp. 1755-1762
JNC VI : The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (1997) Arch Intern Med, 157, pp. 2413-2446
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (1998) Lancet, 352, pp. 837-853
Marre, M., Berrut, G., Bouhanick, B., Fressinaud, Ph., Dissociation between vascular and hormonal actions of calcium antagonists (1993) Current Topics in Pharmacol, 2, pp. 91-97
Calsen, J.E., Kober, L., Torp-Pedersen, C., Johansen, P., Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects (1990) BMJ, 300, pp. 975-978
Samuelsson, O., Pennert, K., Andersson, O., Berglund, G., Hedner, T., Persson, B., Wedel, H., Wilhelmsen, L., Diabetes mellitus and raised serum triglyceride concentration in treated hypertension - Are they of prognostic importance? Observational study (1996) BMJ, 313, pp. 660-663
Medical Research Council Trial of treatment of hypertension in older adults : Principal results (1992) BMJ, 304, pp. 405-412
Passa, Ph., Gauville, C., Bentz, F., Assan, R., Canivet, J., Effets de l'acebutolol sur les réactions endocriniennes et métaboliques induites par une hypoglycémie aigue. Etude chez des sujets normaux et des diabétiques insulino-dépendants (1979) Nouv Presse Méd, 8, pp. 3951-3955
Herings, R.M.C., De Boer, A., Stricker, N.H.Ch., Leufkens, H.G.M., Porsius, A., Hypoglycæmia associated with use of inhibitors of angiotensin converting enzyme (1995) Lancet, 345, pp. 1195-1198
Passa, Ph., Leblanc, H., Marre, M., Effects of enalapril in insulin-dependent diabetic subjects with mild to moderate uncomplicated hypertension (1987) Diabetes Care, 10, pp. 200-204
Marre, M., Chatellier, G., Leblanc, H., Guyenne, T.T., Menard, J., Passa, P., Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria (1988) BMJ, 297, pp. 1092-1095
Lewis, E.J., Hunsiker, L.G., Bain, R.P., Ronde, R.D., For the Collaborative Study Group the effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy (1993) N Engl J Med, 329, pp. 1456-1462
Passa, P., Chatellier, G., On behalf of the Diab.Hycar Study Group the DIAB-HYCAR study (1996) Diabetologia, 39, pp. 1662-1667
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 39 (1998) BMJ, 317, pp. 713-720
Byington, R.P., Craven, T.E., Furberg, C.D., Pahor, M., Isradipine, raised glycoslyated haemoglobin, and risk of cardiovascular events (1997) Lancet, 350, pp. 1075-1076. , letter
Estacio, R.O., Jeffers, B.W., Hiatt, W.R., Biggerstaff, S.L., Gifford, N., Schrier, R.W., The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension (1998) N Engl J Med, 338, pp. 645-652
Tatti, P., Pahor, M., Byington, R.P., Mauro, P.D., Guarisco, R., Strollo, G., Strollo, F., Outcome results of the Fosinopril versus Amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM (1998) Diabetes Care, 21, pp. 597-603
Chatellier, G., Marre, M., Choix du traitement de première intention de l'hypertension artérielle : Doit-on éviter les dihydropyridines chez les diabétiques? (1998) Diabetes & Metabolism, 23, pp. 370-375
